Finasteride/tadalafil

Finasteride/tadalafil

Combination of
Finasteride	5α-reductase inhibitor
Tadalafil	Phosphodiesterase 5 (PDE5) inhibitor
Clinical data
Trade names	Entadfi
AHFS/Drugs.com	Micromedex Detailed Consumer Information
License data	US  DailyMed:  Finasteride and tadalafil
Routes of administration	By mouth
ATC code	G04CB51 ( WHO )
Legal status
Legal status	US: ℞-only [1]
Identifiers
KEGG	D12486

Finasteride/tadalafil, sold under the brand name Entadfi, is a fixed-dose combination medication used for the treatment of benign prostatic hyperplasia (BPH). ^{[1] [2] [3]} It contains finasteride and tadalafil. ^[1] It is taken by mouth. ^[1]

It was approved for medical use in the United States in December 2021. ^{[1] [4]}

Medical uses

Finasteride/tadalafil is indicated to treat benign prostatic hyperplasia (BPH) in men. ^[1]

References

1. "Entadfi- finasteride and tadalafil capsule". DailyMed. Retrieved 24 December 2021.
2. Elkelany OO, Owen RC, Kim ED (2015). "Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus". Therapeutics and Clinical Risk Management. 11: 507–13. doi: 10.2147/TCRM.S80353 . PMC   4386768 . PMID   25848297.
3. Olesovsky C, Kapoor A (August 2016). "Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia". Therapeutic Advances in Urology. 8 (4): 257–271. doi:10.1177/1756287216650132. PMC   5131741 . PMID   27928428.
4. "Veru Announces FDA Approval of Entadfi, a New Treatment for Benign Prostatic Hyperplasia". Veru (Press release). 13 December 2021. Archived from the original on 18 December 2021. Retrieved 17 December 2021.